PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
1.07%
Positive revenue growth while MCHP is negative. John Neff might see a notable competitive edge here.
-6.06%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-10.44%
Negative EBIT growth while MCHP is at 42.33%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-10.44%
Negative operating income growth while MCHP is at 42.33%. Joel Greenblatt would press for urgent turnaround measures.
-4.25%
Negative net income growth while MCHP stands at 32.05%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-4.44%
Negative EPS growth while MCHP is at 42.86%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-2.27%
Negative diluted EPS growth while MCHP is at 35.71%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
-1.21%
Both firms reduce share counts. Martin Whitman would compare buyback intensity relative to free cash flow generation.
-1.72%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
0.46%
Dividend growth under 50% of MCHP's 8.70%. Michael Burry might suspect more pressing needs for cash or weaker earnings power.
102.70%
OCF growth above 1.5x MCHP's 25.32%. David Dodd would confirm a clear edge in underlying cash generation.
243.37%
FCF growth above 1.5x MCHP's 28.47%. David Dodd would verify if the firm’s strategic investments yield superior returns.
91.91%
10Y revenue/share CAGR at 75-90% of MCHP's 113.51%. Bill Ackman would press for new markets or product lines to narrow the gap.
76.29%
5Y revenue/share CAGR above 1.5x MCHP's 47.99%. David Dodd would look for consistent product or market expansions fueling outperformance.
17.50%
3Y revenue/share CAGR at 75-90% of MCHP's 22.81%. Bill Ackman would expect new product strategies to close the gap.
123.71%
10Y OCF/share CAGR at 50-75% of MCHP's 241.40%. Martin Whitman might fear a structural deficiency in operational efficiency.
171.96%
5Y OCF/share CAGR above 1.5x MCHP's 72.86%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
-13.46%
Negative 3Y OCF/share CAGR while MCHP stands at 19.39%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
311.00%
Net income/share CAGR at 50-75% of MCHP's 434.22%. Martin Whitman might question if the firm’s product or cost base lags behind.
66.06%
5Y net income/share CAGR at 50-75% of MCHP's 116.09%. Martin Whitman might see a shortfall in operational efficiency or brand power.
11.12%
Below 50% of MCHP's 50.56%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
100.48%
10Y equity/share CAGR at 50-75% of MCHP's 176.24%. Martin Whitman would note a lag in capital accumulation vs. the competitor.
16.45%
Positive 5Y equity/share CAGR while MCHP is negative. John Neff might see a clear edge in retaining earnings or managing capital better.
5.88%
Positive short-term equity growth while MCHP is negative. John Neff sees a strong advantage in near-term net worth buildup.
361.29%
Dividend/share CAGR of 361.29% while MCHP is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
366.79%
Below 50% of MCHP's 1503.32%. Michael Burry worries the firm returns far less capital to shareholders over 5 years.
652488.96%
3Y dividend/share CAGR above 1.5x MCHP's 516.47%. David Dodd sees a superior short-term capital return strategy if supported by stable earnings.
-2.04%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
-4.60%
Inventory is declining while MCHP stands at 0.17%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
0.68%
Asset growth well under 50% of MCHP's 16.37%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
2.34%
Positive BV/share change while MCHP is negative. John Neff sees a clear edge over a competitor losing equity.
No Data
No Data available this quarter, please select a different quarter.
3.89%
R&D growth drastically higher vs. MCHP's 3.41%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
-8.88%
We cut SG&A while MCHP invests at 1.24%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.